Ofatumumab demonstrates superiority over Aubagio® for relapsing MS: industry news round-up

Written by Sharon Salt, Editor

In this week’s industry news round-up, we cover the latest headlines on two monoclonal antibodies – ofatumumab and eculizumab – for relapsing multiple sclerosis and neuromyelitis optica spectrum disorder (NMOSD). We also cover the approval of istradefylline as an add-on drug to treat ‘OFF’ episodes for Parkinson’s disease. Click on the titles below to navigate to each industry highlight: Ofatumumab demonstrates superiority over Aubagio® for relapsing multiple sclerosis Eculizumab approved by the European Commission for neuromyelitis optica spectrum disorder Istradefylline approved as new add-on drug to treat ‘OFF’ episodes for Parkinson’s disease Ofatumumab demonstrates superiority over Aubagio® for relapsing multiple...

To view the full article, please register now for access

It's completely free